# A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib

> **NCT01324596** · PHASE3 · COMPLETED · sponsor: **University Hospital Southampton NHS Foundation Trust** · enrollment: 1132 (actual)

## Conditions studied

- Lymphoma, Large B-Cell, Diffuse

## Interventions

- **DRUG:** Intravenous
- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT01324596
- **Lead sponsor:** University Hospital Southampton NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04
- **Primary completion:** 2015-04
- **Final completion:** 2015-06
- **Target enrollment:** 1132 (ACTUAL)
- **Last updated:** 2016-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01324596

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01324596, "A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01324596. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*